Nephroblastoma Treatment Market, by Type (Favorable histology and Anaplastic histology), by Drug Type (Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid

Nephroblastoma Treatment Market, by Type (Favorable histology and Anaplastic histology), by Drug Type (Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor. The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy. Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.

Market Dynamics

Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S.

Key features of the study:

  • This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global nephroblastoma treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market
Detailed Segmentation:
  • Global Nephroblastoma Treatment Market, By Type:
  • Favorable histology
  • Anaplastic histology
  • Global Nephroblastoma Treatment Market, By Drug Type:
  • Dactinomycin (Cosmegen)
  • Doxorubicin (Adriamycin)
  • Vincristine (Vincasar PFS, Oncovin)
  • Cyclophosphamide (Cytoxan, Neosar)
  • Etoposide (Toposar, VePesid)
  • Irinotecan (Camptosar)
  • Others
  • Global Nephroblastoma Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Nephroblastoma Treatment Market, By Region:
  • North America
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Type
  • Favorable histology
  • Anaplastic histology
  • By Drug Type
  • Dactinomycin (Cosmegen)
  • Doxorubicin (Adriamycin)
  • Vincristine (Vincasar PFS, Oncovin)
  • Cyclophosphamide (Cytoxan, Neosar)
  • Etoposide (Toposar, VePesid)
  • Irinotecan (Camptosar)
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Merck & Co., Inc.
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Recordati Rare Diseases
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Actiza Pharmaceutical Private Limited
  • Teva Pharmaceutical Industries Ltd.
  • Alvogen
  • Accord Healthcare Ireland Ltd.
  • Baxter
  • Amneal Pharmaceuticals LLC.
  • Cadila Pharmaceuticals Ltd.
  • Company Highlights
  • Xediton Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Type
Market Snapshot, By Drug Type
Market Snapshot, By Distribution Channel
Market Snapshot, By Country
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
PEST Analysis
Epidemiology
Product Launch/Approvals
4. Global Nephroblastoma Treatment Market– COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Demand and Supply Analysis
5. Global Nephroblastoma Treatment Market, By Type, 2017 – 2030, (US$ Million)
Overview
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Favorable histology
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Anaplastic histology
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
6. Global Nephroblastoma Treatment Market, By Drug Type, 2017 – 2030, (US$ Million)
Overview
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Dactinomycin (Cosmegen)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Doxorubicin (Adriamycin)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Vincristine (Vincasar PFS, Oncovin)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Cyclophosphamide (Cytoxan, Neosar)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Etoposide (Toposar, VePesid)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Irinotecan (Camptosar)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Others
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
7. Global Nephroblastoma Treatment Market, By Distribution Channel, 2017 – 2030, (US$ Million)
Overview
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Hospital Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Retail Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Online Pharmacies
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
8. Global Nephroblastoma Treatment Market, By Region, 2017 – 2030, (US$ Million)
Introduction
Market Share Analysis, By Region, 2022 and 2030 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2030
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Recordati Rare Diseases
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Sun Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Actiza Pharmaceutical Private Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Alvogen
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Accord Healthcare Ireland Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Baxter
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Amneal Pharmaceuticals LLC.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Cadila Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Xediton Pharmaceuticals
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
10. Section
Research Methodology
About Us
*Browse 41 market data tables and 43 figures on "Nephroblastoma Treatment Market” - Global forecast to 2030

Loading...

In this report,

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings